Human iPSC-Derived 3D Cardiac Models for Cardiomyopathies: Organoids, Spheroids, and Engineered Heart Tissues as Translational Platforms
Clicks: 21
ID: 320367
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
6.0
/100
21 views
10 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #13 of 62 articles by views in stem cells international
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Cardiomyopathies represent a substantial global health burden, yet progress in developing effective therapies was long constrained by the absence of physiologically relevant human models to understand molecular mechanisms and evaluating interventions. The advent of induced pluripotent stem cell (iPSC) technology has driven major advances in cardiomyopathy research, although important limitations persist. Current iPSC based systems exhibit incomplete cellular maturation, lack functional vasculature and chamber level architecture, and possess an immature extracellular matrix. These factors must be carefully weighed when interpreting disease phenotypes and drug response data. iPSC derived in vitro 3D cardiac tissues have significantly addressed these issues, thereby expanding our ability to model human cardiac disease, offering more physiologically relevant platforms for mechanistic studies, drug screening, and translational research. This concise review synthesizes recent advances in the development of iPSC-derived 3D cardiac systems, such as 3D spheroids, engineered heart tissues (EHTs) and cardiac organoids, their application to modeling various cardiomyopathies including hypertrophic cardiomyopathy, dilated cardiomyopathy, and amyloid-related cardiomyopathies, while discussing critical challenges including cellular maturation, vascularization, and standardization. In this review, emerging technologies and therapeutic strategies have been highlighted that bridge the gap between bench and bedside, demonstrating the translational potential of these models for precision medicine in cardiovascular disease.
| Reference Key |
openalex_W7167814445
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Prabin Upadhyaya |
| Journal | stem cells international |
| Year | 2026 |
| DOI |
10.1093/stmcls/sxag039
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.